Evidence map›Paper›PMID 42439929›Full record

ArticleCancer immunology, immunotherapy : CII2026

Survival outcomes of conversion curative therapy following atezolizumab-bevacizumab in advanced hepatocellular carcinoma.

Ying-Hsin Chen, Wei-Feng Li, Yen-Hao Chen, Ming-Chao Tsai, Yuan-Hung Kuo, Jing-Houng Wang, Chien-Hung Chen, Sheng-Nan Lu, Chih-Chi Wang, Chao-Hung Hung

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ying-Hsin ChenDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung 833, Kaohsiung, Taiwan.
Wei-Feng LiLiver Transplant Center, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Yen-Hao ChenDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Ming-Chao TsaiDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung 833, Kaohsiung, Taiwan.
Yuan-Hung KuoDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung 833, Kaohsiung, Taiwan.
Jing-Houng WangDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung 833, Kaohsiung, Taiwan.
Chien-Hung ChenDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung 833, Kaohsiung, Taiwan.
Sheng-Nan LuDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung 833, Kaohsiung, Taiwan.
Chih-Chi WangLiver Transplant Center, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Chao-Hung HungDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta Pei Road, Niao Sung 833, Kaohsiung, Taiwan. chh4366@yahoo.com.tw.ORCID https://orcid.org/0000-0003-1646-9519

Funding

National Science Council NSTC 114-2321-B-182A-006
6 · The paper itself

Abstract

backgroundThe prognostic value of curative therapies-including liver transplantation, hepatectomy, and local ablation-in patients with advanced hepatocellular carcinoma (HCC) following atezolizumab plus bevacizumab treatment remains unclear. This study evaluated the feasibility of curative therapy and compared survival outcomes between patients who did and did not undergo curative interventions following atezolizumab plus bevacizumab, using a propensity score-matched (PSM) analysis.

methodsWe retrospectively analyzed 318 consecutive patients with advanced HCC who received atezolizumab plus bevacizumab between 2020 and 2024. Overall survival (OS) and progression-free survival (PFS) were defined as the primary and secondary endpoints, respectively. Survival outcomes were estimated using the Kaplan-Meier method and evaluated with multivariate Cox proportional hazards regression, modeling exposure to conversion curative therapy as a time-dependent covariate.

resultsThe objective response rate to atezolizumab plus bevacizumab was 34.6%. Thirty-six patients (11%) subsequently underwent curative therapy, including liver transplantation (n = 8, 2.5%), hepatectomy (n = 11, 3.5%), and local ablation (n = 17, 5.3%). Patients receiving curative therapy demonstrated significantly improved OS (p < 0.001) and PFS (p < 0.001) compared with those who did not, with benefits persisting after PSM analysis. Multivariate Cox regression identified curative therapy as an independent predictor of OS (hazard ratio [HR] 0.398; 95% confidence interval [CI] 0.179-0.885; p = 0.024).

conclusionsIn selected patients with advanced HCC who achieved disease control after atezolizumab-bevacizumab, conversion curative therapy was associated with favorable survival outcomes.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularLiver NeoplasmsAgedFemaleHepatectomyHumansMaleMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabAtezolizumab plus bevacizumabCurative therapyHepatocellular carcinomaOverall survivalProgression-free survival

Identifiers

PMID42439929
PMCPMC13642872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.